Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.
Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.
“The Global Regenerative Medicine Market size was valued at USD 11.6 million in 2018 and is anticipated to grow at a CAGR of 21.2% during the
While I think that there are plenty of long-term buying opportunities being created for stocks in the Financial, Industrial and Information Technology sectors, to name a few, I suspect that many investors might be looking toward the more recession-resistant Health Care sector these days for new i...
Investors are jittery after the sudden departure of French drugmaker Servier from a collaboration in oncology with San Francisco’s Allogene Therapeutics.
- Public-Private Effort to Shift Traditional Model of Hepatitis Management to Primary Care and Help to Expand Care to More People in Need - Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration be...
CytoReason and Pfizer are re-upping their partnership with a $20 million equity investment from Pfizer projected to net $110 million.
Dyania Health, a NYC-based developer of natural language processing technology to drive clinical and synthetic research, raised $5.3m in seed funding
Neukio Biotherapeutics Co. Ltd. has raised $50 million to support preclinical validation and clinical development of new cell therapies for cancer. The series A-1 round was led by CD Capital, Beijing Alwin Asset Management Co. Ltd. and Surplus Capital, with contributions from previous investors Lill…
A majority of the top 10 dividend-yielding names are undervalued.
The signing ceremony of the strategic cooperation agreement between the Shanghai Federation of Industry and Commerce (SFIC) and the Pudong New Area, and the signing ceremony of private enterprises’ investment projects were held at the Zhangjiang Science Hall on 16 September. Projects such as Intuiti…
In this week’s roundup of hires, promotions, and accolades in North Texas, you’ll also find news from Jacobs, HF Sinclair and Holly Energy Partners, Caris Life Sciences, Fossil Group, Deloitte, TRG, Invited, Instil Bio, RealPage, Critical Start, Genuine Article, and others.
“Delveinsight Business Research LLP”As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working in the Diffuse
Pune, Maharashtra, India, September 15 2022 (Wiredrelease) MarketDesk –:Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market research report starts with an elemental introduction along with product definition, product scope, market overview, and product specification. Basic segment classi...
Neukio Biotherapeutics Co. Ltd. has raised $50 million to support preclinical validation and clinical development of new cell therapies for cancer. The series A-1 round was led by CD Capital, Beijing Alwin Asset Management Co. Ltd. and Surplus Capital, with contributions from previous investors Lill…
Major players in the pharmaceutical drug delivery market are 3M Company, Bayer AG, Becton Dickinson And Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson Inc. , Merck & Co Inc, Novartis AG, Pfizer Inc, Sanofi S.New York, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com anno…
Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – BeiGene, Incyte, Genentech, Sound Biologics, Morphotek, Seattle Genetics, PersonGen Bio, Celld Medgadget
Immune Cell Therapy Market Insights : The increasing use of Immune Cell Therapy in Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophageal Cancer,
Gilead Sciences (GILD) – Kite Pharma's CAR T-Cell Therapy Wins European Approval In Refractory Leukemia S Benzinga Gilead claims first CAR-T approval for leukaemia in older adults - pharmaphorum Kite's CAR-T cell therapy Tecartus gets 4th European approval The Pharma Letter Kite's CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia Investing News Network View Full Coverage on Google News
San Francisco’s ArsenalBio announced it raised $220M in Series B funding, one of the largest rounds this year for a cell therapy venture.